Victory Capital Management Inc. Increases Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Victory Capital Management Inc. lifted its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 465.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 44,766 shares of the company's stock after acquiring an additional 36,844 shares during the quarter. Victory Capital Management Inc. owned 0.10% of Omnicell worth $1,685,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in OMCL. Pacer Advisors Inc. lifted its stake in Omnicell by 321,488.8% in the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company's stock worth $39,814,000 after purchasing an additional 1,057,698 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Omnicell by 15.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company's stock valued at $231,374,000 after acquiring an additional 674,824 shares during the period. Jacobs Levy Equity Management Inc. grew its position in Omnicell by 12,425.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 482,488 shares of the company's stock worth $21,731,000 after acquiring an additional 478,636 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Omnicell in the 4th quarter worth approximately $13,687,000. Finally, Exchange Traded Concepts LLC lifted its position in Omnicell by 48.2% in the fourth quarter. Exchange Traded Concepts LLC now owns 566,704 shares of the company's stock valued at $21,325,000 after purchasing an additional 184,213 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Trading Down 3.9 %

NASDAQ OMCL traded down $1.22 during trading on Friday, hitting $30.44. The company had a trading volume of 460,062 shares, compared to its average volume of 497,185. The company's fifty day moving average is $28.37 and its 200-day moving average is $31.27. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -66.17, a price-to-earnings-growth ratio of 143.32 and a beta of 0.77. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48. Omnicell, Inc. has a one year low of $25.69 and a one year high of $77.14.

Analysts Set New Price Targets

Several research analysts recently commented on OMCL shares. Benchmark reaffirmed a "buy" rating and issued a $38.00 target price on shares of Omnicell in a research note on Tuesday, April 30th. Wells Fargo & Company decreased their price objective on shares of Omnicell from $28.00 to $26.00 and set an "equal weight" rating on the stock in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $42.20.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.